Myfenax (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Myfenax, is an antimetabolite presented as an oral dosage form for oral use. It is employed to prevent organ transplant rejection and to treat certain autoimmune diseases such as lupus nephritis.

GNH USA supplies Myfenax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Myfenax (mycophenolate mofetil) is used in immune‑mediated conditions where suppression of lymphocyte activity is required.

Organ transplant rejection: helps prevent rejection of kidney, heart and liver transplants. Lupus nephritis: reduces kidney inflammation in systemic lupus erythematosus. Dermatomyositis: used as part of combination therapy to control disease activity. Vasculitis: employed in refractory cases to suppress immune response. Other autoimmune diseases: may be added to regimens for severe autoimmune disorders.

Myfenax may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, sometimes watery. - Headache: intermittent tension‑type pain. - Tremor: fine shaking of hands. - Abdominal pain: cramping or discomfort. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Severe infections: opportunistic bacterial, viral or fungal infections. - Bone marrow suppression: leukopenia, anemia or thrombocytopenia. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Malignancy risk: increased incidence of certain cancers. - Progressive multifocal leukoencephalopathy (PML): rare but life‑threatening brain infection. - Teratogenicity: birth defects when exposure occurs in pregnancy.

Before initiating Myfenax, several safety considerations should be reviewed.

Pregnancy: contraindicated (Category X) due to high teratogenic risk. Infection risk: monitor for signs of opportunistic infections. Hematologic monitoring: perform regular CBC to detect leukopenia or anemia. Renal function: adjust dosing in severe renal impairment. Drug interactions: review concomitant medicines for potential CYP or absorption interactions. Store at room temperature: keep in the original container, protect from moisture and light.

Myfenax interacts with several drugs; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Cyclosporine: increased mycophenolate exposure, raising toxicity risk. - Tacrolimus: similar interaction leading to higher drug levels. - Live vaccines: risk of severe infection due to immunosuppression. - Antacids containing aluminum or magnesium: reduce mycophenolate absorption.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - Rifampin: may lower mycophenolate concentrations. - Warfarin: potential increase in INR, requiring INR monitoring.